Departments of Molecular Medicine, and Immunology and Microbiology, Scripps Research, La Jolla, California 92037, USA; email:
Annu Rev Immunol. 2020 Apr 26;38:365-395. doi: 10.1146/annurev-immunol-102419-035900. Epub 2020 Jan 27.
Sialic acid-binding immunoglobulin-type lectins (Siglecs) are expressed on the majority of white blood cells of the immune system and play critical roles in immune cell signaling. Through recognition of sialic acid-containing glycans as ligands, they help the immune system distinguish between self and nonself. Because of their restricted cell type expression and roles as checkpoints in immune cell responses in human diseases such as cancer, asthma, allergy, neurodegeneration, and autoimmune diseases they have gained attention as targets for therapeutic interventions. In this review we describe the Siglec family, its roles in regulation of immune cell signaling, current efforts to define its roles in disease processes, and approaches to target Siglecs for treatment of human disease.
唾液酸结合免疫球蛋白型凝集素（Siglecs）表达于免疫系统的大多数白细胞上，在免疫细胞信号转导中发挥关键作用。通过识别作为配体的含有唾液酸的聚糖，它们帮助免疫系统区分自我和非自我。由于它们在人类疾病（如癌症、哮喘、过敏、神经退行性疾病和自身免疫性疾病）中的免疫细胞反应中的细胞类型表达受限和作为检查点的作用，它们已作为治疗干预的靶点引起关注。在这篇综述中，我们描述了 Siglec 家族，及其在调节免疫细胞信号转导中的作用，目前努力确定其在疾病过程中的作用，以及针对 Siglecs 治疗人类疾病的方法。
